Zurich Cantonal Bank
ELVN icon

Zurich Cantonal Bank’s Enliven Therapeutics ELVN Stock Holding History

Zurich Cantonal Bank’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$555K Hold
10,933
– – ﹤0.01% 1881
2026
Q1 		$429K Buy
+10,933
New +$303K ﹤0.01% 1916

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Zurich Cantonal Bank's ELVN Position: Q2 2026 in Review

Zurich Cantonal Bank held its Enliven Therapeutics (ELVN) position steady in Q2 2026 at 10,933 shares worth $555K. The position accounts for ﹤0.01% of the portfolio, ranked #1881.

Zurich Cantonal Bank first reported a position in ELVN in Q1 2026 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Zurich Cantonal Bank held 10,933 shares of Enliven Therapeutics worth $555K as of Q2 2026.
  • Zurich Cantonal Bank left its Enliven Therapeutics share count unchanged in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1881 holding.
  • Zurich Cantonal Bank first reported a position in Enliven Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.